微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 24.35% | -20.56% | -7.67% | 126/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 26.38% | -11.68% | -10.16% | 123/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 29.36% | 14.3% | -5.93% | 117/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 31.21% | 27.13% | 1.81% | 113/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 30.66% | 17.2% | 2.65% | 111/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 29.87% | -48.39% | 16.27% | 119/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 25.69% | -63.17% | 4.63% | 126/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 24.55% | -67.45% | -6.15% | 131/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 26.16% | -68.38% | -54.8% | 123/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 57.88% | -3.72% | -17.02% | 62/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 69.75% | 52.16% | -7.53% | 35/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 75.43% | 87.49% | -8.84% | 29/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 82.74% | 87.64% | 37.63% | 18/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 60.11% | 58.55% | 31.15% | 57/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 45.84% | 17.1% | 13.94% | 85/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 40.23% | -0.69% | -8.76% | 98/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 44.09% | 2% | 16.29% | 84/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 37.92% | -11% | -3.14% | 110/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 39.14% | 2% | -3.37% | 96/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 40.51% | -5.98% | -4.91% | 96/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2020-12-31 | 42.6% | 3.48% | -1.12% | 99/157 | -148.64% | 艾力斯 | 98.7% | 行业排名> |
| 2020-06-30 | 43.08% | 12.93% | 4.65% | 88/157 | 54.17% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 41.17% | -9.26% | -9.26% | 96/157 | -1242.15% | 首药控股 | 99.94% | 行业排名> |
| 2018-12-31 | 45.37% | 49.25% | 18.93% | 78/157 | -211.97% | 泽璟制药 | 99.96% | 行业排名> |
| 2018-06-30 | 38.15% | 48.19% | 25.49% | 78/157 | 53.53% | 微芯生物 | 95.14% | 行业排名> |
| 2017-12-31 | 30.4% | 32.84% | 18.08% | 102/157 | 52.55% | 多瑞医药 | 95.59% | 行业排名> |
| 2017-06-30 | 25.74% | 2% | 12.49% | 89/157 | 47.91% | 微芯生物 | 95.81% | 行业排名> |
| 2016-12-31 | 22.88% | 2% | 2% | 103/157 | 48.46% | 微芯生物 | 96.09% | 行业排名> |